Recce Pharmaceuticals Limited (ASX:RCE) Secures Approval for Phase 3 Clinical Trial
Recce Pharmaceuticals receives approval for a Phase 3 trial of RECCE® 327 in Indonesia for diabetic foot infections.
Recce Pharmaceuticals receives approval for a Phase 3 trial of RECCE® 327 in Indonesia for diabetic foot infections.
Platinum Asset Management (ASX:PTM) declares a special dividend and concludes discussions with Regal while pursuing a turnaround strategy.
Vonex Limited advises shareholders on Swoop and MaxoTel takeover offers, maintaining a recommendation for acceptance of MaxoTel’s cash offer.
Charter Hall Group (ASX:CHC) announces a dividend distribution of AUD 0.2342 per security, payable on 28 February 2025.
Lithium Energy Limited (ASX:LEL) announces amended sale terms with CNGR for the Solaroz Lithium Project, ensuring cash flow and operational funding.
Australian Rare Earths Limited secures a $5M grant to advance the Koppamurra Project, reinforcing its strategic position in the rare earth sector.
Tivan Limited secures a $7.4 million grant for the Speewah Fluorite Project, enhancing Australia’s critical minerals supply chain.
Cynata Therapeutics raises $8.1 million following positive DFU trial results.
Trigg Minerals (ASX:TMG) raises $5 million in a successful Placement driven by investor confidence, funding key exploration projects.
James Bay Minerals (ASX:JBY) raises A$6 million through a placement, boosting exploration at its Independence Gold Project in Nevada.